137 related articles for article (PubMed ID: 25870517)
21. Expanding antitumor therapeutic windows by targeting cancer-specific nicotinamide adenine dinucleotide phosphate-biogenesis pathways.
Chakrabarti G; Gerber DE; Boothman DA
Clin Pharmacol; 2015; 7():57-68. PubMed ID: 25870517
[TBL] [Abstract][Full Text] [Related]
22. Design and discovery of novel quinazolinedione-based redox modulators as therapies for pancreatic cancer.
Pathania D; Sechi M; Palomba M; Sanna V; Berrettini F; Sias A; Taheri L; Neamati N
Biochim Biophys Acta; 2014 Jan; 1840(1):332-43. PubMed ID: 23954204
[TBL] [Abstract][Full Text] [Related]
23. Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone.
Chakrabarti G; Moore ZR; Luo X; Ilcheva M; Ali A; Padanad M; Zhou Y; Xie Y; Burma S; Scaglioni PP; Cantley LC; DeBerardinis RJ; Kimmelman AC; Lyssiotis CA; Boothman DA
Cancer Metab; 2015; 3():12. PubMed ID: 26462257
[TBL] [Abstract][Full Text] [Related]
24. Escaping Death: Mitochondrial Redox Homeostasis in Cancer Cells.
Ciccarese F; Ciminale V
Front Oncol; 2017; 7():117. PubMed ID: 28649560
[TBL] [Abstract][Full Text] [Related]
25. The Pentose Phosphate Pathway as a Potential Target for Cancer Therapy.
Cho ES; Cha YH; Kim HS; Kim NH; Yook JI
Biomol Ther (Seoul); 2018 Jan; 26(1):29-38. PubMed ID: 29212304
[TBL] [Abstract][Full Text] [Related]
26. A spontaneous mutation in the nicotinamide nucleotide transhydrogenase gene of C57BL/6J mice results in mitochondrial redox abnormalities.
Ronchi JA; Figueira TR; Ravagnani FG; Oliveira HC; Vercesi AE; Castilho RF
Free Radic Biol Med; 2013 Oct; 63():446-56. PubMed ID: 23747984
[TBL] [Abstract][Full Text] [Related]
27. NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone.
Moore Z; Chakrabarti G; Luo X; Ali A; Hu Z; Fattah FJ; Vemireddy R; DeBerardinis RJ; Brekken RA; Boothman DA
Cell Death Dis; 2015 Jan; 6(1):e1599. PubMed ID: 25590809
[TBL] [Abstract][Full Text] [Related]
28. Serine catabolism regulates mitochondrial redox control during hypoxia.
Ye J; Fan J; Venneti S; Wan YW; Pawel BR; Zhang J; Finley LW; Lu C; Lindsten T; Cross JR; Qing G; Liu Z; Simon MC; Rabinowitz JD; Thompson CB
Cancer Discov; 2014 Dec; 4(12):1406-17. PubMed ID: 25186948
[TBL] [Abstract][Full Text] [Related]
29. The pentose phosphate pathway and cancer.
Patra KC; Hay N
Trends Biochem Sci; 2014 Aug; 39(8):347-54. PubMed ID: 25037503
[TBL] [Abstract][Full Text] [Related]
30. Knockdown of malic enzyme 2 suppresses lung tumor growth, induces differentiation and impacts PI3K/AKT signaling.
Ren JG; Seth P; Clish CB; Lorkiewicz PK; Higashi RM; Lane AN; Fan TW; Sukhatme VP
Sci Rep; 2014 Jun; 4():5414. PubMed ID: 24957098
[TBL] [Abstract][Full Text] [Related]
31. Quantitative flux analysis reveals folate-dependent NADPH production.
Fan J; Ye J; Kamphorst JJ; Shlomi T; Thompson CB; Rabinowitz JD
Nature; 2014 Jun; 510(7504):298-302. PubMed ID: 24805240
[TBL] [Abstract][Full Text] [Related]
32. A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor.
Elhammali A; Ippolito JE; Collins L; Crowley J; Marasa J; Piwnica-Worms D
Cancer Discov; 2014 Jul; 4(7):828-39. PubMed ID: 24740997
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.
Gross MI; Demo SD; Dennison JB; Chen L; Chernov-Rogan T; Goyal B; Janes JR; Laidig GJ; Lewis ER; Li J; Mackinnon AL; Parlati F; Rodriguez ML; Shwonek PJ; Sjogren EB; Stanton TF; Wang T; Yang J; Zhao F; Bennett MK
Mol Cancer Ther; 2014 Apr; 13(4):890-901. PubMed ID: 24523301
[TBL] [Abstract][Full Text] [Related]
34. Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers.
Cao L; Li LS; Spruell C; Xiao L; Chakrabarti G; Bey EA; Reinicke KE; Srougi MC; Moore Z; Dong Y; Vo P; Kabbani W; Yang CR; Wang X; Fattah F; Morales JC; Motea EA; Bornmann WG; Yordy JS; Boothman DA
Antioxid Redox Signal; 2014 Jul; 21(2):237-50. PubMed ID: 24512128
[TBL] [Abstract][Full Text] [Related]
35. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer.
Győrffy B; Surowiak P; Budczies J; Lánczky A
PLoS One; 2013; 8(12):e82241. PubMed ID: 24367507
[TBL] [Abstract][Full Text] [Related]
36. Modulation of oxidative stress as an anticancer strategy.
Gorrini C; Harris IS; Mak TW
Nat Rev Drug Discov; 2013 Dec; 12(12):931-47. PubMed ID: 24287781
[TBL] [Abstract][Full Text] [Related]
37. Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.
Chini CC; Guerrico AM; Nin V; Camacho-Pereira J; Escande C; Barbosa MT; Chini EN
Clin Cancer Res; 2014 Jan; 20(1):120-30. PubMed ID: 24025713
[TBL] [Abstract][Full Text] [Related]
38. Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.
Bey EA; Reinicke KE; Srougi MC; Varnes M; Anderson VE; Pink JJ; Li LS; Patel M; Cao L; Moore Z; Rommel A; Boatman M; Lewis C; Euhus DM; Bornmann WG; Buchsbaum DJ; Spitz DR; Gao J; Boothman DA
Mol Cancer Ther; 2013 Oct; 12(10):2110-20. PubMed ID: 23883585
[TBL] [Abstract][Full Text] [Related]
39. Role of glutathione in cancer progression and chemoresistance.
Traverso N; Ricciarelli R; Nitti M; Marengo B; Furfaro AL; Pronzato MA; Marinari UM; Domenicotti C
Oxid Med Cell Longev; 2013; 2013():972913. PubMed ID: 23766865
[TBL] [Abstract][Full Text] [Related]
40. TIGAR is required for efficient intestinal regeneration and tumorigenesis.
Cheung EC; Athineos D; Lee P; Ridgway RA; Lambie W; Nixon C; Strathdee D; Blyth K; Sansom OJ; Vousden KH
Dev Cell; 2013 Jun; 25(5):463-77. PubMed ID: 23726973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
